15.49

5.02% 0.74

After Hours: 15.62 0.13 +0.84%

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $15.49, with a volume of 3.86M. It is up +5.02% in the last 24 hours and up +49.52% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Previous Close:

$14.75

Open:

$14.46

24h Volume:

3.86M

Relative Volume:

1.43

Market Cap:

$2.77B

Revenue:

$15.36M

Net Income/Loss:

$-276.48M

P/E Ratio:

-9.6038

EPS:

-1.6129

Net Cash Flow:

$-235.87M

1W Performance:

+6.75%

1M Performance:

+49.52%

6M Performance:

+134.34%

1Y Performance:

+461.23%

1-Day Range:

$14.32

$15.66

1-Week Range:

$14.18

$15.89

52-Week Range:

$2.53

$15.89

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-370-8837

Address

60 HAMPSHIRE STREET, CAMBRIDGE

Employee

192

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	15.49	2.64B	15.36M	-276.48M	-235.87M	-1.6129
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-26	Upgrade	Oppenheimer	Perform → Outperform
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-04-25	Resumed	Guggenheim	Buy
Apr-17-25	Initiated	Wells Fargo	Equal Weight
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

06:43 AM

Jones Trading initiates coverage of Relay Therapeutics (RLAY) with hold recommendation - MSN

06:43 AM

Apr 14, 2026

Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN

Apr 14, 2026

Relay Therapeutics stock hits 52-week high at 14.98 USD By Investing.com - Investing.com Canada

Apr 10, 2026

Relay Therapeutics Hits New 52-Week High After Analyst Upgrade - National Today

Apr 10, 2026

Apr 09, 2026

Earnings Recap: Will Relay Therapeutics Inc benefit from green energy policies2026 Action & Reliable Entry Point Alerts - baoquankhu1.vn

Apr 09, 2026

Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock By Investing.com - Investing.com Australia

Apr 09, 2026

Catinazzo, Relay Therapeutics CFO, sells $257k in RLAY stock - Investing.com

Apr 09, 2026

Relay Therapeutics (NASDAQ: RLAY) CFO logs 19,517-share sale under 10b5-1 plan - Stock Titan

Apr 09, 2026

Rally Mode: Will Relay Therapeutics Inc benefit from government policyRate Cut & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Apr 09, 2026

Relay Therapeutics stock hits 52-week high at 14.98 USD - Investing.com

Apr 09, 2026

Apr 08, 2026

Barclays Raises Price Target for Relay Therapeutics (RLAY) to $2 - GuruFocus

Apr 08, 2026

Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $21 - Moomoo

Apr 08, 2026

Apr 07, 2026

JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY - MarketBeat

Apr 07, 2026